// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























4177 Abstracts

Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).

Tanya Jindal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

TP53

Spatial immunophenotypes of distant metastases and response to immune checkpoint inhibition.

Franziska Erlmeier - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).

Laura Cattaneo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Pembrolizumab

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

Charlotte Stahlfeld - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

IMMU132

Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.

Ahmed Mahmoud - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VIRADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort.

Giorgio Brembilla - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Pembrolizumab

Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.

Veronika Bahlinger - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

IMMU132

The genomic landscape of urothelial carcinoma with high and low ERBB2/HER2 expression.

Agreen Hadadi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Characterization and impact of Wnt5A signaling on outcomes of urothelial carcinoma.

Amirali Salmasi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin.

Jacqueline T Brown - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Exploratory analysis of predictive biomarkers for immune-related adverse events (irAEs) due to checkpoint inhibitors (CPIs) in patients with genitourinary (GU) cancers.

Elham Vosoughi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Sarmad Sadeghi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Gemcitabine

Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.

Christopher J. Hoimes - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Enfortumab vedotin

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Himanshu Nagar - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Atezolizumab

Phase II trial of lurbinectedin combined with avelumab as maintenance therapy for metastatic urothelial carcinoma with stable or responding disease following platinum-based chemotherapy.

Guru P. Sonpavde - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Filgrastim

Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER).

Andrea Necchi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Nivolumab

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

Mauricio Burotto - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Immune checkpoint inhibitors in the peri-operative setting in renal cell carcinoma: A meta-analysis of the randomized clinical trials.

Jorge Esteban Villarrubia - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Characterization of FOLH1 expression in renal cell carcinoma (RCC).

Elizabeth Pan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study.

Chiara Ciccarese - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Ipilimumab

Copyright © 2026. QuantiNova All rights reserved